Your session is about to expire
← Back to Search
Ablation vs Drugs for Rapid Heartbeat (VANISH2 Trial)
VANISH2 Trial Summary
This trial will compare the two most common treatments for VT to see which is more effective.
VANISH2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVANISH2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.VANISH2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Antiarrhythmic Drug Therapy
- Group 2: VT catheter ablation
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Frequently Asked Questions
What results is the research team expecting from this trial?
"This medical study, with a total duration of 8 years that includes data from the pilot trial, is aiming to observe ventricular tachycardia storms for at least 14 days post-randomization. As secondary objectives, it will measure any type of ventricular arrhythmia episode after the two week period and evaluate ablation procedural complications or antiarrhythmic drug adverse effects (which may necessitate a subsidiary investigation depending on the complexity of obtained data)."
Has Antiarrhythmic Drug Therapy been explored in past research endeavors?
"Antiarrhythmic Drug Therapy was first researched in 2011 at Eastbourne General Hospital, with 48 studies already completed. Currently 20 trials are ongoing and the bulk of them take place in London, Ontario."
How many participants are enrolled in this clinical trial?
"Recruitment for this medical trial concluded on June 20th 2022. As of now, there are 120 active trials with tachycardia and ventricular involvement and 20 different studies exploring Antiarrhythmic Drug Therapy currently recruiting participants."
Are there presently any open slots for enrollment in this research endeavor?
"This trial has now closed to recruitment, having been originally posted on October 1st 2016 and last updated June 20th 2022. Currently, there are 120 studies seeking participants with tachycardia, ventricular arrhythmia, as well as 20 trials for Antiarrhythmic Drug Therapy requiring patient enrolment."
To what end is Antiarrhythmic Drug Therapy typically utilized?
"The use of antiarrhythmic drugs is beneficial for cardiothoracic surgical interventions and treating life-threatening ventricular arrhythmias, restoring sinus rhythm, or preventing recurrent ventricular fibrillation."
How many facilities are executing this clinical trial?
"London Health Sciences Centre in London, Ontario, Queen's University Health Sciences Centre in Kingston, Tennessee and St. Mary's Hospital in Kitchener, British Columbia are some of the many localities where this research is recruiting participants from. An additional 20 sites have been identified as suitable for recruitment."
Has the FDA authorized Antiarrhythmic Drug Therapy?
"The antiarrhythmic drug therapy was granted a score of 3, owing to its approval following thorough clinical studies in Phase 4."
Share this study with friends
Copy Link
Messenger